A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Amphotericin B Liposome

Lipid-based Polyene Antifungal class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2025-08-06
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.7M in CY2024 Part D spend2K claims · 410 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Amphotericin B Liposome used for?

Amphotericin B Liposome is a Lipid-based Polyene Antifungal medication tracked in Medicare Part D.

Is there a generic for Amphotericin B Liposome?

No. Amphotericin B Liposome is brand-only with no generic equivalents currently in market.

How much does my plan pay for Amphotericin B Liposome?

NADAC pricing data not currently available for this drug.

Is Amphotericin B Liposome on the FDA shortage list?

No. Amphotericin B Liposome is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Lipid-based Polyene Antifungal1 alternative in D1
01
Amphotericin B
Brand: AmBisome
Lowest NADAC
5Generic mfrs
$39,114CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.